皮尔芬尼在纤维性疾病中的使用:我们到目前为止知道什么?
Aldo Torre1, Froylan David Martínez-Sánchez2,3, Sofía Mercedes Narvaez-Chávez3
1Metabolic Unit, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubiran", Mexico City, Mexico.
Immunity, inflammation and disease
|July 5, 2024
概括
皮尔芬尼具有抗炎和抗纤维作用,具有治疗纤维性疾病的潜力,如异常性肺纤维化等. 需要进一步的研究来证实其广泛的治疗疗效.
科学领域:
- 药理学 药理学是指药理学的学科.
- 纤维化研究 纤维化研究
- 炎症研究 炎症研究
背景情况:
- 皮尔芬尼具有显著的抗炎和抗纤维素特性.
- 它通过多个分子途径起作用,调节细胞因子分泌,细胞亡和纤维细胞激活.
- 这些效应将皮尔芬尼定位为纤维状况的潜在治疗剂.
研究的目的:
- 审查目前关于皮尔芬尼对各种纤维性疾病的影响的证据.
- 评估皮尔芬尼作为治疗慢性纤维状况的治疗策略的潜力.
- 为了巩固关于皮尔芬尼的抗纤维活性的发现.
主要方法:
- 对动物模型和临床试验的文献综述.
- 对调查皮尔芬尼的分子机制的研究进行分析.
- 综合证据关于pirfenidone在各种纤维状况中的有效性.
主要成果:
- 皮尔芬尼已在治疗异常性肺纤维化方面得到广泛应用.
- 有证据表明,它对间歇性肺病,心肌纤维化,淋巴细胞病,皮肤痕和肝脏疾病有有益作用.
- 该药物表现出广泛的抗炎和抗纤维作用.
结论:
- 皮尔芬尼是治疗各种纤维性疾病的有前途的治疗候选药物.
- 它的抗炎和抗纤维作用得到了临床前和临床数据的支持.
- 需要进行额外的临床试验,以充分确定pirfenidone在所有纤维状况中的有效性.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
Ultrasound II: Endoscopic Ultrasound and FibroScan
95
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
95
Pleural Effusion II: Symptoms and Management
162
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
162
Introduction to Fibroblasts
3.1K
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
156
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
156


